<DOC>
	<DOCNO>NCT02901288</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy two shorten regimen newly diagnose smear positive drug susceptible pulmonary tuberculosis comparison World Health Organization recommend standard 6-month regimen .</brief_summary>
	<brief_title>Shortened Regimens Drug-susceptible Pulmonary Tuberculosis</brief_title>
	<detailed_description>1 . Design : The study multi-center , randomize , control non-inferiority trial . 2 . Population : patient newly diagnose drug-susceptible pulmonary TB fulfill inclusion exclusion criterion . 3 . Investigational regimen : Experimental group 1 regimen consist levofloxacin , isoniazid , rifampicin , ethambutol pyrazinamide 4.5 month . Experimental group 2 regimen consist isoniazid , rifampicin , ethambutol pyrazinamide 4.5 month . The control group WHO recommend regimen conmposed isoniazid , rifampicin , ethambutol pyrazinamide 2 month , follow isoniazid , rifampicin 4 month . Dosage : isoniazid 300mg ( give daily ) , rifampin 450mg ( less 50kg , give daily ) 600mg ( 50kg , give daily ) , pyrazinamide 1500mg ( less 50kg , give daily ) 30mg/kg ( 50kg , daily ) , ethambutol 750mg ( less 50kg , daily ) 1000mg ( 50kg , daily ) , levofloxacin 600mg ( less 50kg , give daily ) 800mg ( 50kg , daily ) .. 4 . Trial objective : evaluate shorten regimen inferior standard treatment term efficacy safety new smear positive pulmonary TB patient . 5 . Primary Secondary outcome measure : The primary efficacy outcome measure include ( ) percentage participant TB recurrence/relapse 24 month end treatment ; ( b ) percentage participant treatment failure either 4.5 month 6 month randomization . ( ) Time sputum smear culture conversion within intensive phase . ( b ) Sputum smear conversion proportion treatment completion . ( c ) Number adverse drug reaction occur treatment follow-up period . ( ) Radiological manifestation change TB lesion cavity . ( e ) Patients adherence rate . 6 . Sample Size : Approximately 3900 participant enrol randomized 1:1:1 ratio either Experimental group1 , Experimental group2 control group . 7 . Blinding : The study open-label study . 8 . Assessment follow-up : All patient follow 2 year completion treatment .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>1 . Is willing able give inform consent participate trial treatment followup ( sign witness consent patient illiterate ) . 2 . Is aged 1865 year . 3 . Has twice positive acidfast bacillus ( AFB ) sputum smear positive sputum culture result , along chest xray image consistent active pulmonary tuberculosis . 4 . Newly diagnose case receive antiTB treatment le one month 5 . Urine Human Chorionic Gonadotropin ( UHCG ) negative must agree use effective contraception trial period . 6 . Has Alanine aminotransferase（ALT）and Total bilirubin（TBil） less 2 time upper limit normal ; Creatinine clearance rate （CrCI） 30ml/min ; Hemoglobin 7.0g/dL ; Platelet（PLT）more 50 x10^9/L study entry . 1 . Concomitant severe cardiovascular , liver , kidney , nervous system , hematopoietic system disease , concomitant neoplastic disease . Or extensive lesion respiratory insufficiency . 2 . Uncontrolled diabetes mellitus . 3 . Concomitant mental disorder . 4 . Is HIV positive . 5 . Is critically ill , judgment investigator , fit study unlikely complete full course study . 6 . Is know pregnant breastfeeding . 7 . Is unable unwilling comply treatment , assessment , followup schedule . 8 . Is take medication contraindicate medicine trial regimen study . 9 . Has know allergy drug treatment regimen . 10 . Is currently take part another trial . 11 . Has QTc interval 480ms .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>shorten regimen</keyword>
	<keyword>clinical trial</keyword>
</DOC>